News and Announcements
Alcidion TechKnow Investor Roadshow Interview
- Published November 17, 2016 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
17th November 2016, ASX Announcement
Alcidion Group Limited (ASX:ALC) today announced that Executive Director, Mr. Nathan Buzza’s interview from the TechKnow Invest Roadshow is available on the Alcidion website.
Mr. Buzza provides a comprehensive overview of Alcidion as an investment opportunity and of the medical technology market as a whole.
The TechKnow event is the premier investor focused technology event in Australasia, attracting over 700 investors interested in being educated about investment opportunities in the technology space. The event visits three major Australian cities for each roadshow. Mr. Buzza presented Alcidion to investors at the event in Melbourne, Sydney and Brisbane in late October 2016.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
